Education Level Is a Strong Prognosticator in the Subgroup Aged More Than 50 Years Regardless of the Molecular Subtype of Breast Cancer: A Study Based on the Nationwide Korean Breast Cancer Registry Database by �젙以�
│ http://www.e-crt.org │1114 Copyright ⓒ 2017 by  the Korean Cancer Association
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Cancer Res Treat. 2017;49(4):1114-1126
pISSN 1598-2998, eISSN 2005-9256
https://doi.org/10.4143/crt.2016.528
Open Access
Education Level Is a Strong Prognosticator in the Subgroup Aged 
More Than 50 Years Regardless of the Molecular Subtype of Breast Cancer: 
A Study Based on the Nationwide Korean Breast Cancer Registry Database
Original Article
Purpose
This study investigated the role of the education level (EL) as a prognostic factor for breast
cancer and analyzed the relationship between the EL and various confounding factors.
Materials and Methods
The data for 64,129 primary breast cancer patients from the Korean Breast Cancer Registry
were analyzed. The EL was classified into two groups according to the education period; the
high EL group ( 12 years) and low EL group (< 12 years). Survival analyses were performed
with respect to the overall survival between the two groups. 
Results
A high EL conferred a superior prognosis compared to a low EL in the subgroup aged > 50
years (hazard ratio, 0.626; 95% confidence interval [CI], 0.577 to 0.678) but not in the sub-
group aged  50 years (hazard ratio, 0.941; 95% CI, 0.865 to 1.024). The EL was a signif-
icant independent factor in the subgroup aged > 50 years according to multivariate
analyses. The high EL group showed more favorable clinicopathologic features and a higher
proportion of patients in this group received lumpectomy, radiation therapy, and endocrine
therapy. In the high EL group, a higher proportion of patients received chemotherapy in the
subgroups with unfavorable clinicopathologic features. The EL was a significant prognosti-
cator across all molecular subtypes of breast cancer. 
Conclusion
The EL is a strong independent prognostic factor for breast cancer in the subgroup aged 
> 50 years regardless of the molecular subtype, but not in the subgroup aged  50 years. 
Favorable clinicopathologic features and active treatments can explain the main causality
of the superior prognosis in the high EL group. 
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Introduction
The prognostic role of the education level (EL) in breast
cancer is largely unknown. Although the EL has occasionally
been suggested to be a prognostic factor for breast cancer,
previous studies have not provided consistent results on this
relationship. Some papers reported that a higher EL was 
associated with higher survival rates [1-4] but others 
reported no correlation between the EL and breast cancer
survival [5-7]. Furthermore, some papers presented totally
opposite results, suggesting that patients with a high EL had
a higher mortality [8-11]. Therefore, more evidence is needed
to determine the role of the EL as a prognostic factor for
breast cancer. 
Although the EL is a significant prognostic factor in breast
cancer, there is very little information on the relationship 
between the EL and the prognosis of breast cancer. Only a
few papers have investigated the relationship between the
EL and breast cancer prognosis directly [2,5,10], and the
other papers have dealt with the EL or breast cancer as a part
of their investigation, e.g., breast cancer as a part of all can-
cers, or the EL as a part of the socioeconomic status. Most 
papers only reported the hazard ratio or relative risk of the
EL with respect to mortality in breast cancer, and they sel-
dom reported further analyses of the relationship between
the EL and breast cancer prognosis. For example, there is lit-
tle information on the following question: “To which sub-
group of breast cancer patients could the prognostic impact
of EL be applied?”
Although some studies stated that the EL was a significant
prognosticator in breast cancer, they barely described the
plausible causality regarding how the EL can affect the prog-
nosis of breast cancer. Many possible confounding factors 
between the EL and breast cancer prognosis can make it dif-
ficult to interpret the EL as a prognostic factor on its own.
Therefore, it is essential to adequately adjust for these con-
founding factors for precise analyses of the relationship 
between the EL and the breast cancer prognosis. Further-
more, as a relatively small number of enrolled subjects have
been the major obstacles to the establishment of the EL as a
prognostic factor, an adequate number of subjects are needed
to maintain the statistical power of subgroup analyses, which
could be used to determine the effects of various confound-
ing factors on the EL as a prognostic factor for breast cancer.
In this study, an attempt was made to categorize the con-
founding factors that could be associated with the EL into
three groups: biological factors, treatment factors, and other
factors. The biological factors cover the clinicopathologic fac-
tors, including age, body mass index (BMI), tumor size,
nodal positivity, stage, hormonal receptor (HR), human epi-
dermal growth factor receptor 2 (HER2), histologic grade,
and lymphovascular invasion. The treatment factors include
the operation period, surgery, radiation therapy, chemother-
apy, and hormonal therapy. Other factors include all factors
other than biological and treatment factors. 
Currently, adjuvant treatments for breast cancer are pla-
nned based on the molecular subtypes according to the 
expression of the estrogen receptor, progesterone receptor,
and HER2. The prognostic impact of the EL on each molecu-
lar subtype of breast cancer has not been reported. Therefore,
it is necessary to examine the prognostic impact of the EL on
each molecular subtype. 
Since 1996, the Korean Breast Cancer Society has collected
nationwide data for breast cancer patients in the Republic of
Korea by developing the Korean Breast Cancer Registry pro-
gram, and a large amount of data has been accumulated [12].
This study attempted to validate the role of the EL as a prog-
nostic factor for breast cancer, and carry out subgroup analy-
ses using this database. The causality between EL and breast
cancer through which the EL can affect the prognosis of
breast cancer and the prognostic effect of EL on the molecular
subtypes of breast cancer were also investigated. 
Materials and Methods
1. Patients
The Korean Breast Cancer Society has collected nationwide
breast cancer data prospectively since 1996; retrospective
data collection was also allowed when a participating hospi-
tal had its own breast cancer database. The total number of
patients registered in the Korean Breast Cancer Registry at
the time of this study was 156,632. Because the survival data
had been updated up to December 31, 2014, 4,689 patients,
who underwent surgery after January 1, 2015, were exclu-
ded. After further excluding 78,987 patients because of a lack
of information on education (956 patients with stage IV at the
initial diagnosis, and 7,871 patients with a Tis lesion) the data
of 64,129 patients were finally analyzed. The institutional 
review boards approved this study.
2. Definitions of education period and EL
The education system in South Korea consists of five pro-
grams; 6 years of elementary school, 3 years of middle
school, 3 years of high school, 2 or 4 years of college or uni-
versity, and more than 2 years of graduate school. The edu-
cation period was divided into five groups according to the
length of the education period: the no diploma group (< 6
years), elementary school group (6-8 years), middle school
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group (9-11 years), high school group (12-13 years), and col-
lege group ( 14 years). The EL was classified further into
two groups: the high EL group ( 12 years) and the low EL
group (< 12 years). In this study, kindergarten or preschool
programs were excluded.
3. Clinicopathologic parameters
The patients’ ages were defined as the age at the time of
the diagnosis of the primary breast cancer. The TNM staging
was described according to the seventh edition of the Amer-
ican Joint Committee on Cancer. The HR status was defined
as positive when the immunohistochemistry tests for either
estrogen or progesterone receptors were positive, and was
defined as negative when both tests were negative. HER2
was defined as negative when the immunohistochemistry 
results were negative or 1+, and positive when the results
were 3+. When the results were 2+, the positivity of HER2
was defined according to the results of fluorescence in situ
hybridization. The histological grade was defined using the
modified Scarff-Bloom-Richardson grading system. Lym-
phovascular invasion was defined as positive when either
lymphatic invasion or vascular invasion was positive, and as
negative when both tests were negative. The BMI was 
defined as the ratio of the body weight in kilograms to the
square of the height in meters. All operations with curative
intent for breast cancer patients were classified as breast con-
serving surgery or total mastectomy according to the extent
of surgery for the breast tissue. The molecular subtypes were
classified into four categories, including HR(+)/HER2(–),
HR(+)/HER2(+), HR(–)/HER2(+), and HR(–)/HER2(–) 
according to the expression of HR and HER2. 
4. Statistical analyses
A two sample t test and Pearson’s chi-square test were
used to determine the differences in the clinicopathologic
characteristics between pairs of groups. The p-value for the
trend was calculated using the linear by linear association
test in a Pearson’s chi-square test. All survival analyses were
carried out with respect to the overall survival, and the time
duration of the overall survival was defined as the time from
surgery to death from any cause. The Kaplan-Meier estima-
tor was used to analyze the survival rates and a log-rank test
was used to determine the significance of the differences 
between two or more survival curves. A Cox-proportional
hazards model was used for univariate and multivariate
analyses, and the HR was calculated using a 95% confidence
interval (CI). All statistical analyses, except for the forest plot,
were carried out using IBM SPSS Statistics ver. 20.0 (IBM
Corp., Armonk, NY), and the forest plot was produced using
Microsoft Excel (Microsoft Office Professional Plus 2010). All
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tests were two-sided, and a p-value of < 0.05 was considered
significant. The biological model, treatment model, and com-
bined model were designed for multivariate analyses. In the
biological model, nine factors, including age, tumor size,
node positivity, stage, HR, HER2, histologic grade, lympho-
vascular invasion, and BMI, were used to adjust for the EL.
In the treatment model, five factors, including the operation
period, operation, radiation therapy, chemotherapy, and hor-
monal therapy, were used. In the combined model, all four-
teen factors described above were used.  
Results
1. Clinicopathologic characteristics
The total number of subjects was 64,129, and the mean age
of all subjects was 49.8±10.7 years. Their operation dates were
between January 1987 and December 2014, and the mean fol-
low-up period was 71.3±51.7 months (range, 0 to 335 months).
The total number of deaths during the period was 6,010 (9.4%).
According to the length of the education period, the high
school group showed the highest frequency (n=25,464, 39.7%),
followed in order by the college group (n=18,241, 28.4%), mid-
dle school group (n=9,955, 15.5%), elementary school group
(n=8,434, 13.2%), and no diploma group (n=2,035, 3.2%). The
frequencies of the low and high EL groups were 31.8%
(n=20,424) and 68.2% (n=43,705), respectively. Table 1 lists the
clinicopathologic characteristics according to the education 
period and EL. The patients’ mean age decreased with increas-
ing education period, and the proportion of patients with the
following features was increased; age  50 years, tumor size 
 2 cm, negative lymph node, stage I, positive hormone recep-
tor, negative HER2, low histologic grade. In addition, as the
education period became longer, the proportion of patients
who received lumpectomy, radiation therapy, and hormonal
therapy increased. The same results were obtained from a
comparison of the high and low EL groups, except for
chemotherapy. The proportion of patients who received
chemotherapy in the high and low EL groups was similar.
Similar findings were observed in the subgroup aged  50
years and the subgroup aged > 50 years (S1 Table). In the sub-
group aged  50 years, a higher proportion of patients in the
low EL group received chemotherapy (p < 0.001), and in the
subgroup aged > 50 years, there was no difference in the pro-
portion of patients with respect to HER2 expression (p=0.218).
2. Survival analyses of all subjects
Survival analyses according to the education period revea-
led significant differences among all five education period
groups, and a longer education period conferred a better prog-
nosis (log-rank test, all p < 0.05) (Fig. 1A). Survival analyses
according to the EL showed that the high EL group had a bet-
ter prognosis than the low EL group (log-rank test, p < 0.001)
(Fig. 1B). Subgroup analyses with a forest plot revealed the
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Fig. 1.  Overall survival curves according to the education period (A) and education level (B) in all subjects. a)Statistical sig-
nificance. 
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Total
Age (yr)
Tumor size (cm)
Node positivity
Stage
Hormonal receptor
HER2
Histologic grade
Operation 
Radiation therapy
Chemotherapy
Hormonal therapy
≤ 50
> 50
≤ 2
> 2
No
Yes
I
II, III
Negative
Positive
Negative
Positive
1, 2
3
Lumpectomy
Mastectomy
No
Yes
No
Yes
No
Yes
0.677
0.941
0.626
0.654
0.733
0.632
0.725
0.606
0.730
0.824
0.618
0.648
0.791
0.590
0.785
0.725
0.738
0.653
0.701
0.355
0.764
0.834
0.631
Characteristic Hazard ratio Forest plot
0.643
0.865
0.577
0.597
0.689
0.580
0.679
0.535
0.689
0.759
0.575
0.601
0.707
0.544
0.725
0.656
0.695
0.603
0.650
0.310
0.720
0.764
0.573
95% CI
0.712
1.024
0.678
0.717
0.780
0.688
0.773
0.686
0.772
0.894
0.664
0.699
0.885
0.640
0.850
0.802
0.785
0.708
0.757
0.407
0.810
0.912
0.695
< 0.001
   0.160
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
< 0.001
p-value
0.3 0.5 0.7 0.9 1.1
Fig. 2.  Subgroup analyses with a forest plot for the effects of the education level with respect to the overall survival according
to the clinicopathologic characteristics in all subjects. In the forest plot, a HR value less than 1 favors a high EL against low
EL. CI, confidence interval; HER2, human epidermal growth factor receptor 2; EL, education level.
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prognoses of the high EL group to be better than those of the
low EL group in all subgroups, except for the age  50 years
subgroup (Fig. 2). The lower HRs of the high EL group were
more prominent in the subgroups with more favorable clini-
copathologic features; tumor size  2 cm, negative lymph
node, stage I, positive HR, negative HER2, and low histologic
grade. With respect to the treatment modalities, a lower HR
of the high EL group was most prominent in the subgroup
without chemotherapy. 
3. Survival analyses of the subgroup aged > 50 years and the
subgroup aged  50 years
In the subgroup aged > 50 years, the high EL group showed
superior survival than the low EL group both by the log-rank
test (p < 0.001) (Fig. 3B) and by the Cox proportional hazards
model (hazard ratio, 0.626; 95% CI, 0.577 to 0.678; p < 0.001)
(Table 2, Fig. 2). A longer education period conferred a better
prognosis than a shorter education period, except between the
high school group and college group (all p < 0.001, except for
p=0.063 between the high school group and the college group)
(Fig. 3A). In the subgroup aged  50 years, no significant sur-
vival difference was observed between the high and low EL
groups according to both the log-rank test (p=0.160; data not
shown) and the Cox proportional hazards model (hazard
ratio, 0.941; 95% CI, 0.865 to 1.024; p=0.160) (Fig. 2). In addi-
tion, there was no survival difference between each education
period, except for between the elementary school group and
college group (p=0.024, data not shown) and between the high
school group and college group (p=0.020, data not shown). In
the subgroup aged > 50 years, subgroup analyses showed that
the high EL group had superior prognoses to the low EL
group in all subgroups (S2 Fig.). 
4. Univariate and multivariate analyses
For all subjects, univariate analyses showed that all of the
following 15 factors were statistically significant: the EL (haz-
ard ratio, 0.677; 95% CI, 0.643 to 0.712; p < 0.001), age, tumor
size, node positivity, stage, HR, HER2, histologic grade, lym-
phovascular invasion, BMI, operation period, operation, radia-
tion therapy, chemotherapy, and hormonal therapy (S3 Table).
Multivariate analyses showed that the EL was a statistically
significant independent factor in the biological model (hazard
ratio, 0.869; 95% CI, 0.798 to 0.945; p < 0.001) and the treatment
model (hazard ratio, 0.794; 95% CI, 0.743 to 0.849; p < 0.001),
but not in the combined model (hazard ratio, 0.974; 95% CI,
0.878 to 1.082; p=0.625). Although HER2 lost its significance
only in the biological model, the stage and BMI lost their sig-
nificance in both the biological model and combined model. 
In the subgroup aged > 50 years, the 14 factors mentioned
above, except for age, were statistically significant in univari-
ate analyses, and the EL was a significant independent prog-
nosticator in all three models in multivariate analyses (Table
2): biological model (hazard ratio, 0.691; 95% CI, 0.615 to 0.778;
p < 0.001), treatment model (hazard ratio, 0.723; 95% CI, 0.649
to 0.804; p < 0.001), combined model (hazard ratio, 0.821; 95%
CI, 0.71 to 0.948; p=0.007). 
5. Analysis of treatment modalities
For all subjects, a higher proportion of patients received
lumpectomy, radiation therapy, and endocrine therapy in the
high EL group compared to the low EL group (S4 Table). In
subgroup analyses, these findings were consistent regardless
of age, tumor size, node positivity, and HR. With respect to
chemotherapy, although there was no significant differences
between the high and low EL groups in all patient groups, a
higher proportion of patients in the high EL group received
chemotherapy in the pathologically unfavorable subgroups
with a tumor size > 2 cm, positive node, and negative HR, in
subgroup analyses. In the high EL group, a higher proportion
of patients received lumpectomy in the subgroups with both
a tumor size  2 cm and a tumor size > 2 cm. In the subgroup
of lumpectomy, a higher proportion of patients received radi-
ation therapy in the high EL group. In the subgroup with a
positive hormone receptor, a higher proportion of patients 
received endocrine therapy in the high EL group. In the sub-
group aged  50 years, a much higher proportion of patients
received chemotherapy in the lower EL group compared to
the subgroup aged > 50 years. 
In the subgroup aged > 50 years, a higher proportion of 
patients in the high EL group received chemotherapy in the
cases with unfavorable clinicopathologic features, such as
tumor size > 2 cm and positive nodal metastasis compared to
the low EL group (Table 3). The proportion of patients who
received chemotherapy in the subgroup with a negative HR
(p=0.084) and those who received radiation therapy in the sub-
group with lumpectomy (p=0.164) was similar.
6. EL and the molecular subtypes of breast cancer
For all subjects, a high EL conferred better prognoses than a
low EL in all molecular subtypes of breast cancer, including
HR(+)/HER2(–) (p < 0.001), HR(+)/HER2(+) (p=0.003), HR(–)
/HER2(+) (p=0.013), and HR(–)/HER2(–) (p=0.004) subtypes
(S5 Fig.). The prognostic influence of EL was most significant
in the HR(+)/HER2(–) subtype and least significant in the
HR(–)/HER2(+) subtype. In the subgroup aged > 50 years, a
high EL conferred a superior prognosis than a low EL across
all molecular subtypes with the highest and lowest signifi-
cance in the HR(+)/HER2(–) subtype (p < 0.001) and HR(+)/
HER2(+) subtype (p=0.014), respectively (S6 Fig.).
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Discussion
Although several papers have reported the prognostic role
of EL in breast cancer, the results were not consistent and
they are still controversial [1-11,13-17]. These inconsistent 
results regarding the prognostic role of the EL in breast can-
cer prompted this study, which found that the EL is a strong
favorable prognostic factor for breast cancer; the high EL
group showed a better prognosis than the low EL group
(hazard ratio, 0.677; 95% CI, 0.643 to 0.712; p < 0.001) (S3
Table). Log-rank tests also showed that the high EL group
had a superior prognosis than the low EL group (p < 0.001)
(Fig. 1B) and that there were significant differences among
all five education period groups and a longer education 
period conferred a better prognosis (all p < 0.05) (Fig. 1A).
Multivariate analyses showed that the EL was an independ-
ent significant prognostic factor in the biological model (haz-
ard ratio, 0.869; 95% CI, 0.798 to 0.945; p < 0.001) and the
treatment model (hazard ratio, 0.794; 95% CI, 0.743 to 0.849;
p < 0.001), but not in the combined model (hazard ratio,
0.974; 95% CI, 0.878 to 1.082; p=0.625) (S3 Table). 
After confirming the prognostic role of the EL in unse-
lected breast cancer patients, the prognostic influence of the
EL was investigated further in each subgroup of breast can-
cer patients. Thus far, only a few papers have reported sub-
group analyses of the EL in breast cancer. Albano et al. [3]
reported that the breast cancer mortality rates were higher
among women with less education than in those with more
education (37.0 and 31.1 per 100,000, respectively, for black
women, and 25.2 and 18.6 per 100,000, respectively, for white
women). Kim et al. [10] reported that less than a high school
education was associated with lower breast cancer mortality
among white women (odds ratio [OR], 0.73; 95% CI, 0.6 to
0.9) but not among black women (OR, 1.1; 95% CI, 0.5 to 2.3).
In this study, the EL was a strong independent favorable
prognostic factor only in the subgroup aged > 50 years (log-
rank test, p < 0.001) (Cox-proportional hazards model; haz-
ard ratio, 0.626; 95% CI, 0.577 to 0.678) (Table 2, Figs. 2 and
3B), but not in the subgroup aged  50 years (Cox propor-
tional hazards model, hazard ratio, 0.941; 95% CI, 0.865 to
1.024; Fig. 2) according to subgroup analysis. The prognoses
of the high EL group were superior to those of the low EL
group in all subgroups except for the subgroup aged  50
years, regardless of the following factors: tumor size, nodal
positivity, stage, HR, HER2, histologic grade, operation, 
radiation therapy, chemotherapy, and hormonal therapy
(Fig. 2). In the subgroup aged > 50 years, subgroup analysis
showed that the high EL group had superior prognoses to
the low EL group in all subgroups (S2 Fig.), and multivariate
analysis showed that the EL was a significant independent
prognosticator in all three models (Table 2): biological model
(hazard ratio, 0.691; 95% CI, 0.615 to 0.778; p < 0.001), treat-
ment model (hazard ratio, 0.723; 95% CI, 0.649 to 0.804; p <
0.001), combined model (hazard ratio, 0.821; 95% CI, 0.710 to
0.948; p=0.007). Dalton et al. [18] reported that women with
higher education showed a reduced OR compared to women
with a basic/high school education (OR, 0.83; 95% CI, 0.73
to 0.94) for high-risk breast cancer only in postmenopausal
women, but they did not carry out survival analyses. 
Although several papers have stated that the EL is a sig-
nificant prognostic factor in breast cancer, the mechanisms
through which EL plays the role of a prognostic factor are
largely unknown. From the results of this study, an attempt
was made to suggest several plausible explanations for these
mechanisms in the following three aspects: biological aspect,
treatment aspect, and aspects other than biological and treat-
ment aspects.
First, in biological aspects, the high EL group showed more
favorable biological features than the low EL group, which
could partially explain the superior survival in the high EL
group. As shown in Table 1, the mean age of the high EL
group was lower and the proportion of patients aged  50
years was larger in the high EL group than in the low EL
group. The proportion of patients with the following features
was higher in the high EL group: age  50 years, tumor size
 2 cm, negative lymph node, stage I, positive hormone 
receptor, negative HER2, and low histologic grade. In the
subgroup aged > 50 years, similar findings to that mentioned
above were obtained (S1 Table). These findings strongly sug-
gest that a high EL is closely associated with favorable bio-
logical features leading to a superior prognosis. Several
studies reported similar findings to the present results
[13,18,19]. Rutqvist et al. [13] reported that the breast cancer
stage was significantly higher among patients with a low
level of education. Dalton et al. [18] reported that women
with a higher education showed a reduced OR compared to
women with basic/high school education only (OR, 0.88;
95% CI, 0.80 to 0.96) for high-risk breast cancer with size >
20 mm, lymph-node positive, high histologic grade, and hor-
mone receptor negative. The diagnostic timing of primary
breast cancer could play a key role in explaining the differ-
ences in the biological features according to the EL. In the
high EL group, the early diagnosis of breast cancer could be
the reason for the lower mean age at the first diagnosis and
more favorable biological features, which might have 
resulted in better survival rates in the high EL group than
the low EL group.
Second, in the treatment aspect, the patients in the high EL
group were presumed to receive treatments more actively,
which might have resulted in better survival rates. The pro-
portion of patients who received lumpectomy, radiation
therapy, and endocrine therapy was higher in the high EL
group because the clinicopathologic features were more 
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favorable in that group (Table 1), regardless of the tumor
size, nodal positivity, stage, and HR status (S4 Table). 
Despite the favorable clinicopathologic features, the propor-
tion of patients who received chemotherapy in the high EL
group was not lower than that in the low EL group. In the
subgroup aged > 50 years, the proportion of patients who 
received radiation therapy in the subgroup with a lumpec-
tomy and who received endocrine therapy in the subgroup
with a positive HR was higher in the high EL group. In 
addition, a higher proportion of patients in the high EL
group received chemotherapy in the subgroups with more
unfavorable clinicopathologic features, such as a larger
tumor size, positive lymph node, and advanced stage (Table 3).
These findings strongly suggest that an active attitude 
towards treatments in the high EL group could have con-
tributed to the superior prognosis to that in the low EL
group. Griggs et al. [20] reported that an EL less than high
school was significantly associated with reduced doses of 
adjuvant chemotherapy (OR, 3.07; 95% CI, 1.57 to 5.99).
Bouchardy et al. reported that patients form a low social class
underwent breast-conserving surgery, hormonal therapy,
and chemotherapy less frequently, particularly in the case of
axillary lymph node involvement [21].
Third, there could be factors other than biological or treat-
ment factors that are related to the effects of the EL on the
survival rates of breast cancer patients. In the subgroup aged
> 50 years, multivariate analyses showed that the EL was a
significant independent factor in all three models (Table 2).
In particular, in the combined model, the EL was still a sig-
nificant factor after adjusting for biological and treatment fac-
tors. These findings suggest that there could be factors other
than the biological or treatment factors that could have con-
tributed to the superior survival in the high EL group. A
range of factors were presumed to be included in this cate-
gory: adherence to breast cancer screening [22], socioeco-
nomic status [21,23-25], exercise [26], diet [26], smoking
[27-29], etc. 
Although this study showed that the EL was a strong prog-
nostic factor in unselected breast cancer patients and in the
subgroup aged > 50 years, the EL was not a prognosticator
in the subgroup aged  50 years. Most importantly, as the
low EL patients in the subgroup aged  50 years received 
adjuvant therapy more actively than those in the subgroup
aged > 50 years, the survival difference could be reduced in
the subgroup aged  50 years. Although the proportions of
low EL patients who received chemotherapy and hormonal
therapy in the subgroup aged > 50 years were 68.3% and
55.1%, respectively, those in the subgroup aged  50 years
were 83.2% and 59.4%, respectively. Second, the prognostic
effect of the EL could be weakened in the subgroup aged 
 50 years because the majority of the subjects in the sub-
group aged  50 years were high EL patients, with the pre-
sumption that the EL is a strong prognostic factor in breast
cancer. The proportion of high EL in the subgroup aged > 50
years and the subgroup aged  50 years was 27.7% and
72.3%, respectively. Third, as the overall survival rate was
higher in the subgroup aged  50 years than in the subgroup
aged > 50 years, the impact of the EL could be less prominent
in the subgroup aged  50 years. 
The influence of the EL on the molecular subtypes of breast
cancer remains unknown, and no previous results on this
issue could be found. This study examined the prognostic
role of the EL in the molecular subtypes after classifying all
breast cancers into four categories: HR(+)/HER2(–), HR(+)/
HER2(+), HR(–)/HER2(+), and HR(–)/HER2(–) subtypes. In
this study, the EL was a significant prognostic factor across
all molecular subtypes of breast cancer, including the HR(+)/
HER2(–), HR(+)/HER2(+), HR(–)/HER2(+), and HR(–)/
HER2(–) subtypes for both the all subjects group and the sub-
group aged > 50 years (log-rank tests, all p < 0.05) (S5 and S6
Figs.). The significance was highest in the HR(+)/ HER2(–)
subtype. 
In this study, a large number of subjects (n=64,129) were
analyzed using the nationwide breast cancer registry data-
base from the Korean Breast Cancer Society. Although such
a large number of subjects could provide considerable statis-
tical power and reduce various biases, even in subgroup
analyses, the present study had several limitations. The data
were incomplete, particularly the data on adjuvant treatment
modalities. The missing data rates were as follows: 1.8% for
surgery, 13.1% for radiation therapy, 9.9% for chemotherapy,
33.2% for endocrine therapy. The impact of anti-HER2 ther-
apy could not be analyzed due to insufficient data. Although
an attempt was made to adjust for as many confounding fac-
tors as possible, most of the other confounding factors, such
as socioeconomic status, smoking, drinking, exercise, etc.,
could not be analyzed due to insufficient data. 
In conclusion, the EL is a strong independent favorable
prognostic factor in breast cancer only in the subjects aged 
> 50 years, but not in the subjects aged  50 years. Favorable
clinicopathologic features and active treatment could explain
most of this observation. The EL was a significant prognostic
factor in breast cancer regardless of the molecular subtype.
The early detection of cancer and the receipt of appropriate
treatments without omission are important for improving
the overall survival for breast cancer patients aged more than
50 years with a low EL. Overall, the EL is one of the most 
important prognostic factors that should be considered care-
fully in a clinical setting.
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